Trajectories of change in symptom severity in patients with fibromyalgia: exploratory analyses of a randomised controlled trial.
Fibromyalgia
Latent class growth analysis
Polysymptomatic distress scale
Trajectory
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
29
12
2020
accepted:
27
01
2021
pubmed:
17
2
2021
medline:
1
12
2021
entrez:
16
2
2021
Statut:
ppublish
Résumé
The clinical picture of fibromyalgia (FM) symptoms fluctuates, and the symptom severity varies within and between patients. The current study aimed to identify groups of PDS trajectories and to explore differences in baseline characteristics between the potential groups of trajectories. We included patients from a completed randomised controlled trial, in total 170 patients diagnosed with FM according to the ACR 2010 criteria. The mean age was 40 years, and 94% were women. Symptom severity was assessed by the Polysymptomatic distress scale (PDS) [range 0 (no symptoms) to 31] at four timepoints over 13-18 months. Latent class growth analysis was used to identify patient trajectories based on their response pattern on the PDS. Potential differences in baseline characteristics between the trajectories were compared using appropriate statistical tests. Two distinct PDS trajectories were identified with 110 patients (65%) classified as the "no improvement" group and 60 (35%) as the "some improvement" group. Mean PDS scores at pre-baseline were ≥ 20 in both groups. At 12 months, the groups diverged, mean (SD) PDS score was 14 (3.82) in the "some improvement" group and 21 (4.12) in the "no improvement" group. There were no significant differences in baseline characteristics between the groups of PDS trajectories. We identified one group of FM patients that improved slightly during the study period and one group that not improved. There were no differences in baseline characteristics between the two groups.
Identifiants
pubmed: 33590330
doi: 10.1007/s00296-021-04801-x
pii: 10.1007/s00296-021-04801-x
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
691-697Subventions
Organisme : Helse Sør-Øst RHF
ID : 2016015
Références
Schaefer CP et al (2016) Fibromyalgia outcomes over time: results from a prospective observational study in the United States. Open Rheumatol J 10(1):109–121. https://doi.org/10.2174/1874312901610010109
doi: 10.2174/1874312901610010109
pubmed: 28077978
pmcid: 5204069
Galvez-Sánchez CM, Reyes del Paso GA (2020) Diagnostic criteria for fibromyalgia: critical review and future perspectives. J Clin Med 9:1219. https://doi.org/10.3390/jcm9041219
doi: 10.3390/jcm9041219
pmcid: 7230253
Wolfe F et al (1990) The American college of rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum. 33(2):160–172. https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780330203
Wolfe F et al (2010) The American college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 62(5):600–610. https://doi.org/10.1002/acr.20140
doi: 10.1002/acr.20140
Clauw DJ (2014) Fibromyalgia: a clinical review. JAMA 311(15):1547–1555. https://doi.org/10.1001/jama.2014.3266
doi: 10.1001/jama.2014.3266
pubmed: 24737367
Clauw DJ (2009) Fibromyalgia: an overview. Am J Med. 122(12 Supplement): S3–S13. https://doi.org/10.1016/j.amjmed.2009.09.006
Wolfe F et al (2015) The use of polysymptomatic distress categories in the evaluation of fibromyalgia (FM) and FM severity. J Rheumatol 42(8):1494–1501. https://doi.org/10.3899/jrheum.141519
doi: 10.3899/jrheum.141519
pubmed: 26077414
pmcid: 4755344
Wolfe F (2009) Fibromyalgianess. Arthritis Care Res 61(6):715–716. https://doi.org/10.1002/art.24553
doi: 10.1002/art.24553
Wolfe F et al (2011) Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 38(6):1113–1122. https://doi.org/10.3899/jrheum.100594
doi: 10.3899/jrheum.100594
pubmed: 21285161
Fors EA et al (2020) Fibromyalgia 2016 criteria and assessments: comprehensive validation in a Norwegian population. Scand J Pain 20(4):663–672. https://doi.org/10.1515/sjpain-2020-0002
doi: 10.1515/sjpain-2020-0002
pubmed: 32609652
Haugmark T et al (2018) Effects of a community-based multicomponent rehabilitation programme for patients with fibromyalgia: protocol for a randomised controlled trial. BMJ Open 8(6):e021004. https://doi.org/10.1136/bmjopen-2017-021004
doi: 10.1136/bmjopen-2017-021004
pubmed: 29866731
pmcid: 5988178
Steen E, Haugli L (2000) The body has a history: an educational intervention programme for people with generalised chronic musculoskeletal pain. Patient Educ Couns 41(2):181–195. https://doi.org/10.1016/S0738-3991(99)00077-4
doi: 10.1016/S0738-3991(99)00077-4
Zangi HA, Haugli L (2017) Vitality training - A mindfulness- and acceptance-based intervention for chronic pain. Patient Educ Couns 100(11):2095–2097. https://doi.org/10.1016/j.pec.2017.05.032
doi: 10.1016/j.pec.2017.05.032
Wolfe F et al (2019) Diagnosis of fibromyalgia: disagreement between fibromyalgia criteria and clinician-based fibromyalgia diagnosis in a university clinic. Arthritis Care Res 71(3):343–351. https://doi.org/10.1002/acr.23731
doi: 10.1002/acr.23731
Schwarz G (1978) Estimating the dimension of a model. Ann Stat 6(2):461–464. https://doi.org/10.1214/aos/1176344136
doi: 10.1214/aos/1176344136
Jung T, Wickrama KAS (2008) An introduction to latent class growth analysis and growth mixture modeling. Soc Personal Psychol Compass 2(1):302–317. https://doi.org/10.1111/j.1751-9004.2007.00054.x
doi: 10.1111/j.1751-9004.2007.00054.x
StataCorp (2019) Stata statistical software: release 16. StataCorp LLC, College Station
Walitt B et al (2011) The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol 38(10):2238–2246. https://doi.org/10.3899/jrheum.110026
doi: 10.3899/jrheum.110026
pubmed: 21765102
Littlejohn G, Guymer E (2018) Central processes underlying fibromyalgia. Euro Med J 4(3):79–86
Provan SA et al (2021) The changing states of fibromyalgia in patients with axial spondyloarthritis: results from BSRBR-AS. Rheumatology. https://doi.org/10.1093/rheumatology/keaa888
doi: 10.1093/rheumatology/keaa888
pubmed: 33404655
Bergenheim A et al (2019) Stress levels predict substantial improvement in pain intensity after 10 to 12 years in women with fibromyalgia and chronic widespread pain: a cohort study. BMC Rheumatol 3(1):21. https://doi.org/10.1186/s41927-019-0072-9
doi: 10.1186/s41927-019-0072-9
Rooij AD et al (2013) Predictors of multidisciplinary treatment outcome in fibromyalgia: a systematic review. Disabil Rehabil 35(6):437–449. https://doi.org/10.3109/09638288.2012.699582
doi: 10.3109/09638288.2012.699582
pubmed: 22889312
Van Den Houte M et al (2017) Differentiating progress in a clinical group of fibromyalgia patients during and following a multicomponent treatment program. J Psychosom Res 98:47–54. https://doi.org/10.1016/j.jpsychores.2017.05.004
doi: 10.1016/j.jpsychores.2017.05.004
Haugmark T, et al. (2021) Effects of a mindfulness- and acceptance-based group-programme followed by physical activity for patients with fibromyalgia: a randomised controlled trial (Submitted).
Andruff H et al (2009) Latent class growth modelling: a tutorial. Tutor Quant Methods Psychol 5:11–24. https://doi.org/10.20982/tqmp.05.1.p011
doi: 10.20982/tqmp.05.1.p011
Srinivasan S et al (2019) The problematic nature of fibromyalgia diagnosis in the community. ACR Open Rheumatol 1(1):43–51. https://doi.org/10.1002/acr2.1006
doi: 10.1002/acr2.1006
pubmed: 31777779
pmcid: 6857982